



Step Therapy Criteria

2025 MCSNP

Last Updated: 10/29/2024

DULOXETINE THERAPY - UHCMR

Products Affected

- Drizalma Sprinkle

Details

| Criteria | |
|----------|---|
| | Step 1: Formulary, generic duloxetine. Step 2: Drizalma. Approve for continuation of prior therapy. |

FANAPT THERAPY - UHCMR

Products Affected

- Fanapt
- Fanapt Titration Pack

Details

| | |
|-----------------|---|
| Criteria | Step 1: Two of the following oral, single-ingredient, formulary, generic atypical antipsychotics: asenapine, aripiprazole, paliperidone, olanzapine, quetiapine, risperidone, ziprasidone. Step 2: Fanapt. Approve for continuation of prior therapy. |
|-----------------|---|

LEVOLEUCOVORIN THERAPY - UHCMR

Products Affected

- Levoleucovorin INJ 50MG
- Levoleucovorin Calcium

Details

| | |
|-----------------|------------------------|
| Criteria | Non-Proxy Step Therapy |
|-----------------|------------------------|

LYBALVI THERAPY - UHCMR

Products Affected

- Lybalvi

Details

| | |
|-----------------|--|
| Criteria | Step 1: Two of the following oral, single-ingredient, formulary, generic atypical antipsychotics: asenapine, aripiprazole, paliperidone, olanzapine, quetiapine, risperidone, ziprasidone. Step 2: Lybalvi. Approve for continuation of prior therapy. |
|-----------------|--|

RHO KINASE INHIBITOR THERAPY - UHCMR

Products Affected

- Rhopressa
- Rocklatan

Details

| | |
|-----------------|--|
| Criteria | Step 1: One of the following: Lumigan, generic latanoprost, Vyzulta. Step 2: Rhopressa, Rocklatan |
|-----------------|--|

RIVASTIGMINE PATCH THERAPY - UHCMR

Products Affected

- Rivastigmine Transdermal System

Details

| | |
|-----------------|--|
| Criteria | Step 1: Generic, oral rivastigmine capsule. Step 2: Generic rivastigmine transdermal systems |
|-----------------|--|

RYTARY THERAPY - UHCMR

Products Affected

- Rytary

Details

| | |
|-----------------|---|
| Criteria | Step 1: One of the following: generic carbidopa/levodopa IR, generic carbidopa/levodopa ER tablets, or carbidopa/levodopa ODT. Step 2: Rytary |
|-----------------|---|

SECUADO THERAPY - UHCMR

Products Affected

- Secuado

Details

| | |
|-----------------|--|
| Criteria | Step 1: Two of the following oral, single-ingredient, formulary, generic atypical antipsychotics: asenapine, aripiprazole, paliperidone, olanzapine, quetiapine, risperidone, ziprasidone. Step 2: Secuado. Approve for continuation of prior therapy. |
|-----------------|--|

SNRI THERAPY

Products Affected

- Fetzima
- Fetzima Titration Pack

Details

| | |
|-----------------|--|
| Criteria | Step 1: Generic venlafaxine extended release capsules. Step 2: Fetzima. Approve for continuation of prior therapy. |
|-----------------|--|

TOPICAL IMMUNOMODULATOR THERAPY

Products Affected

- Pimecrolimus
- Tacrolimus OINT

Details

| | |
|-----------------|--|
| Criteria | Step 1: Any two of the following formulary topical agents: desonide ointment, Ala-Cort 2.5% or hydrocortisone 2.5% cream, hydrocortisone 2.5% ointment, generic aug betamethasone 0.05%, fluocinonide 0.05%. Step 2: Generic pimecrolimus, generic tacrolimus topical |
|-----------------|--|

UCERIS ORAL THERAPY - UHCMR

Products Affected

- Budesonide Er

Details

| | |
|-----------------|--|
| Criteria | Step 1: Brand Apriso or generic mesalamine 1.2g, AND generic sulfasalazine. Step 2: Generic budesonide ER tablet |
|-----------------|--|

ULORIC THERAPY - UHCMR

Products Affected

- Febuxostat

Details

| | |
|-----------------|---|
| Criteria | Step 1: Oral, generic allopurinol. Step 2: Generic febuxostat |
|-----------------|---|

VUMERITY THERAPY - UHCMR

Products Affected

- Vumerity

Details

| | |
|-----------------|---|
| Criteria | Step 1: Any one formulary dimethyl fumarate-containing product. Step 2: Vumerity. |
|-----------------|---|

ZONISADE SUSPENSION THERAPY

Products Affected

- Zonisade

Details

| | |
|-----------------|--|
| Criteria | Step 1: Generic zonisamide capsule. Step 2: Zonisade suspension. Approve for continuation of prior therapy. |
|-----------------|--|

Plans are insured through UnitedHealthcare Insurance Company or one of its affiliated companies, a Medicare Advantage organization with a Medicare contract and a Medicare-approved Part D sponsor. Enrollment in the plan depends on the plan's contract renewal with Medicare.

[<OVEX3386716_000>]

Formulary ID# 00025003

Y0066_130404_093413 CMS Approved